LEVULAN

Peak

aminolevulinic acid hydrochloride

NDATOPICALSOLUTION
Approved
Dec 1999
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

solution, photosensitization occurs through the metabolic conversion of aminolevulinic acid to protoporphyrin IX (PpIX), a photosensitizer, which accumulates in the skin. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic…

Clinical Trials (2)

NCT06160492Phase 3Recruiting

Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)

Started Apr 2025
144 enrolled
5-aminolevulinic AcidFluorescence-guided Resection
NCT04020653Phase 2Withdrawn

A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria

Started Sep 2019
0
Malaria

Loss of Exclusivity

LOE Date
Jan 12, 2038
144 months away
Patent Expiry
Jan 12, 2038

Patent Records (5)

Patent #ExpiryTypeUse Code
11697028
Oct 13, 2036
U-804
12290700
Oct 13, 2036
U-804
11179574
Oct 13, 2036
U-804
11446512
Jan 17, 2037
U-804
11690914
Jan 12, 2038
U-3163